公开(公告)号：US20230138306A1

公开(公告)日：2023-05-04

申请号：US17955895

申请日：2022-09-29

申请人： NICOVENTURES TRADING LIMITED

发明人： MICHAEL ZAWADZKI ,  KAI TANG ,  STEVEN LEE ALDERMAN ,  THOMAS H. POOLE

IPC分类号： A61K9/00 ,  A61K31/194 ,  A61K31/4439 ,  A61K47/38 ,  A61K45/06

摘要： The disclosure provides a composition configured for oral use, the composition including at least one filler, water, a basic amine, and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a logP value of from about 1 to about 12. At least a portion of the basic amine is associated with at least a portion of the organic acid or the alkali metal salt thereof. The association is in the form of a basic amine-organic acid salt, an ion pair between the basic amine and a conjugate base of the organic acid, or a combination of both. The organic acid is a monoester of a dicarboxylic acid or is a carotenoid derivative having one or more carboxylic acids.

公开(公告)号：US20230136792A1

公开(公告)日：2023-05-04

申请号：US17907732

申请日：2021-04-01

申请人： Sirtsei Pharmaceuticals, Inc.

发明人： Michael Friedrich Ackermann ,  Kelly J. Abernathy ,  Gregory Cooksey Rigdon ,  Stephen E. Butts

IPC分类号： A61K31/4245 ,  A61K31/454 ,  A61K31/422 ,  A61K31/424 ,  A61K31/506 ,  A61K31/4439

摘要： The present invention relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of age-related diseases by administering a compound of Formula 1 to a subject in need thereof. The invention further relates to methods of treating, delaying the onset of, slowing the progression of, or reducing the severity of premature aging disorders by administering a compound of Formula 1 to a subject in need thereof.

公开(公告)号：US20230133600A1

公开(公告)日：2023-05-04

申请号：US17796076

申请日：2021-01-28

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： Hong LIU ,  Jian LI ,  Jingjing PENG ,  Xiong XIE ,  Wenhao DAI ,  Shulei HU ,  Chunpu LI ,  Leike ZHANG ,  Zhenming JIN ,  Yechun XU ,  Gengfu XIAO ,  Haitao YANG ,  Fang BAI ,  Xi CHENG ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： A61K31/404 ,  A61K31/4412 ,  A61K31/4025 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/4535 ,  A61K31/453 ,  A61K31/4525 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/4155

摘要： A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.

公开(公告)号：US11638706B2

公开(公告)日：2023-05-02

申请号：US17093194

申请日：2020-11-09

申请人： PTC Therapeutics, Inc.

发明人： Suresh Babu ,  Anuradha Bhattacharyya ,  Seongwoo Hwang ,  Minakshi Jani ,  Young-choon Moon ,  Nadiya Sydorenko

IPC分类号： C07D417/14 ,  A61K31/4468 ,  A61K31/506 ,  A61K31/433 ,  C07D403/14 ,  C07D405/14 ,  C07D401/12 ,  C07D417/04 ,  C07D487/04 ,  C07D401/04 ,  C07D409/14 ,  C07D487/10 ,  C07D237/20 ,  C07D471/10 ,  C07D413/14 ,  C07D487/08 ,  C07D405/12 ,  C07D403/10 ,  C07D471/08 ,  C07D403/12 ,  C07D417/10 ,  C07D401/14 ,  C07D417/12 ,  A61K31/50 ,  A61K31/415 ,  A61P25/28 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5513 ,  G01N33/68

摘要： The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

公开(公告)号：US20230132378A9

公开(公告)日：2023-04-27

申请号：US17827041

申请日：2022-05-27

申请人： UNM RAINFOREST INNOVATIONS

发明人： Graham Timmins ,  Ke Jian Liu ,  Rong Pan

IPC分类号： A61K31/409 ,  A61P9/10 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377

摘要： A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or at risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.

公开(公告)号：US20230131804A1

公开(公告)日：2023-04-27

申请号：US17906580

申请日：2021-03-17

申请人： Metacrine, Inc.

发明人： Kenneth SONG ,  Hubert CHEN ,  Brandee WAGNER ,  Nicholas D. SMITH

IPC分类号： A61K31/4439 ,  A61K45/06 ,  A61P1/16 ,  A61P1/04 ,  A61P35/00

摘要： Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.

公开(公告)号：US11633478B2

公开(公告)日：2023-04-25

申请号：US17576496

申请日：2022-01-14

申请人： Azurity Pharmaceuticals, Inc.

发明人： Zeus Pendon ,  Steven Dinh

IPC分类号： A61K47/10 ,  A61K47/02 ,  A61K47/24 ,  A61K47/38 ,  A61K9/10 ,  A61K31/4439 ,  A61K47/14

摘要： Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

公开(公告)号：US11633415B2

公开(公告)日：2023-04-25

申请号：US16498897

申请日：2018-03-30

申请人： THE BROAD INSTITUTE, INC. ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： Steven M. Corsello ,  Todd R. Golub ,  Eric Stefan ,  Robert Hilgraf

IPC分类号： A61K31/7064 ,  A61K31/4439 ,  A61K31/498

摘要： The present invention includes CSNK1A1 inhibitors that are useful in treating or preventing a cancer in a subject. In certain embodiments, the cancer comprises a hematological cancer, such as but not limited to acute myeloid leukemia (AML) and/or MDS (myelodysplastic syndrome, including 5q-MDS). In other embodiments, the cancer comprises colon cancer.

公开(公告)号：US20230119894A1

公开(公告)日：2023-04-20

申请号：US17639552

申请日：2020-09-03

申请人： Japan Tobacco Inc.

发明人： Yasuko MERA ,  Sohei KATSUMI ,  Chihiro OKUMA ,  Seiya MOCHIDA

IPC分类号： A61K31/4155 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/7034 ,  A61K31/4985 ,  A61P3/10

摘要： One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic complications, and that is characterized by combinational use of an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors; and a therapeutic or prophylactic method that is for diabetes, obesity, or diabetic complications, and that is characterized by administering an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors.

公开(公告)号：US20230116770A1

公开(公告)日：2023-04-13

申请号：US17875216

申请日：2022-07-27

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Stephen GARDELL ,  Anthony B. PINKERTON ,  Eduard SERGIENKO ,  Hampton SESSIONS

IPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

摘要： Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.